GPC Biotech begins satraplatin phase-2 trial with metastatic breast cancer patients

By Angela McDaniels

Seattle, Nov. 2 - GPC Biotech AG said it began a phase-2 study evaluating satraplatin in patients with metastatic breast cancer who have received no more than one prior chemotherapy treatment regimen.

The multicenter study is being managed by US Oncology and aims to determine the drug's response rate.

Satraplatin is currently in a phase-3 registrational trial as a second-line chemotherapy treatment for patients with hormone-refractory prostate cancer, and the company plans to explore the potential of satraplatin in a number of additional tumor types.

"Despite advancements in treating breast cancer, it is important to continue to find and develop effective therapies, as patients with advanced disease often do not respond to existing treatments or will eventually relapse," said Joyce O'Shaughnessy, co-director of US Oncology's Breast Cancer Research Committee and director of Breast Cancer Prevention at Baylor-Charles A. Sammons Cancer Center in Dallas.

"Our partnership with GPC Biotech enables us to advance the development of satraplatin, while also minimizing our expenses and preserving the upside associated with this promising drug for our company and our shareholders," said Rajesh C. Shrotriya, chief executive officer of GPC partner Spectrum Pharmaceuticals Inc.

GPC Biotech is a biopharmaceutical company headquartered in Martinsried/Munich, Germany, that develops drugs for the treatment of cancer.

US Oncology, headquartered in Houston, is a health care services networks dedicated exclusively to cancer treatment and research.

Spectrum Pharmaceuticals is based in Irvine, Calif., and develops prescription drug products for the treatment of cancer and other unmet medical needs.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.